Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma

34Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: To evaluate the safety and efficacy of carbon ion radiotherapy (C-ion RT) for 80 years or older patients with hepatocellular carcinoma (HCC). Methods: Eligibility criteria of this retrospective study were: 1) HCC confirmed by histology or typical hallmarks of HCC by imaging techniques of four-phase multidetector-row computed tomography or dynamic contrast-enhanced magnetic resonance imaging; 2) no intrahepatic metastasis or distant metastasis; 3) no findings suggesting direct infiltration of the gastrointestinal tract; 4) performance status ≤2 by Eastern Cooperative Oncology Group classification; and 5) Child-Pugh classification A or B. Patients received C-ion RT with 52.8 Gy (RBE) or 60.0 Gy (RBE) in four fractions for usual cases and 60.0 Gy (RBE) in 12 fractions for close-to-gastrointestinal tract cases. Toxicities were classified using the National Cancer Institute's Common Terminology Criteria for Adverse Events (Version 4.0). Results: Between March 2011 and November 2015, 31 patients were treated. The median follow-up period of all patients was 23.2 months (range: 8.4-55.3 months). Median age at the time of registration of C-ion RT was 83 years (range: 80-95 years). Child-Pugh grade A and B were 27 patients and 4 patients, respectively. The 2-year estimated overall survival, local control, and progression-free survival rates were 82.3%, 89.2%, and 51.3%, respectively. No patients had Grade 2 or higher acute toxicities (within 3 months after C-ion RT). One patient experienced progression in Child-Pugh classification from A to B within 3 months after C-ion RT. In late toxicities, Grade 3 encephalopathy was observed in 3 patients, and 2 improved with medication. Conclusions: C-ion RT was effective with minimal toxicities for 80 years or older patients with hepatocellular carcinoma. Trial registration:UMIN000020571: date of registration, 14 January 2016, retrospectively registered.

References Powered by Scopus

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

14234Citations
N/AReaders
Get full text

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

5076Citations
N/AReaders
Get full text

Hepatocellular carcinoma

3947Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: Results of a single-center retrospective case control study

51Citations
N/AReaders
Get full text

Strategic application of radiotherapy for hepatocellular carcinoma

47Citations
N/AReaders
Get full text

Stereotactic body radiation therapy for early-stage hepatocellular carcinoma–a systematic review on outcome

30Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Shiba, S., Abe, T., Shibuya, K., Katoh, H., Koyama, Y., Shimada, H., … Nakano, T. (2017). Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma. BMC Cancer, 17(1). https://doi.org/10.1186/s12885-017-3724-4

Readers over time

‘17‘18‘19‘20‘21‘22‘23‘240481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

52%

Researcher 7

33%

Professor / Associate Prof. 3

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 14

70%

Nursing and Health Professions 3

15%

Biochemistry, Genetics and Molecular Bi... 2

10%

Chemistry 1

5%

Save time finding and organizing research with Mendeley

Sign up for free
0